Skip to main content
Accolade, Inc. (ACCD)
NASDAQ: ACCD · IEX Real-Time Price · USD
7.89
-1.30 (-14.15%)
At close: Apr 26, 2024, 4:00 PM
7.96
+0.07 (0.89%)
After-hours: Apr 26, 2024, 7:49 PM EDT

Accolade Revenue

In the fiscal year ending February 28, 2024, Accolade had annual revenue of $414.29M with 14.09% growth. Revenue in the quarter ending February 28, 2024 was $124.83M with 26.06% year-over-year growth.

Revenue (ttm)
$414.29M
Revenue Growth
+14.09%
P/S Ratio
1.47
Revenue / Employee
$174,807
Employees
2,370
Market Cap
610.75M USD

Revenue Chart

History

Fiscal Year End Revenue Change Growth
Feb 28, 2024414.29M51.15M14.09%
Feb 28, 2023363.14M53.12M17.13%
Feb 28, 2022310.02M139.66M81.98%
Feb 28, 2021170.36M37.85M28.57%
Feb 28, 2020132.51M37.70M39.76%
Feb 28, 201994.81M17.98M23.41%
Feb 28, 201876.83M--
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
Pharming Group 272.57M
Evolus 202.09M
Aurinia Pharmaceuticals 175.51M
Atrion 169.33M
Arcturus Therapeutics Holdings 166.80M
OrthoPediatrics 148.73M
Nurix Therapeutics 80.89M
Autolus Therapeutics 1.70M
Revenue Rankings

ACCD News

More News